Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
暂无分享,去创建一个
[1] H. Piwnica-Worms,et al. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. , 1992, Science.
[2] C. Turck,et al. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.
[3] T. Lagerweij,et al. WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas , 2012, Molecular Cancer Therapeutics.
[4] C. Koh,et al. Mitosis-targeted anti-cancer therapies: where they stand , 2012, Cell Death and Disease.
[5] Y Taya,et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.
[6] M. Meuth,et al. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells. , 2011, International journal of oncology.
[7] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[8] Domenico Grieco,et al. The spindle checkpoint requires cyclin-dependent kinase activity. , 2003, Genes & development.
[9] L. Cascione,et al. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma , 2014, Oncotarget.
[10] Tianhong Li,et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial , 2010, Investigational New Drugs.
[11] Nicola J. Curtin,et al. DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.
[12] A. Venook,et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Hirai,et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil , 2010, Cancer biology & therapy.
[14] G. Inman,et al. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. , 1995, The EMBO journal.
[15] P. Nurse,et al. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation , 1997, The EMBO journal.
[16] P. Renhowe,et al. Inhibitors of kinesin motor proteins--research and clinical progress. , 2005, Current opinion in drug discovery & development.
[17] P. Clarke,et al. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. , 2007, Molecular cell.
[18] Tsuyoshi Arai,et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.
[19] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[20] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[21] M. McDevitt,et al. Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias , 2012, Clinical Cancer Research.
[22] A. Maitra,et al. MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts , 2011, Clinical Cancer Research.
[23] Erich A. Nigg,et al. Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.
[24] V. Costanzo,et al. Mechanisms of replication fork protection: a safeguard for genome stability , 2012, Critical reviews in biochemistry and molecular biology.
[25] A. Eastman,et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. , 2002, Molecular cancer therapeutics.
[26] L. del Vecchio,et al. The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs , 2015, Cell Death and Differentiation.
[27] P. Clarke,et al. Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest , 2010, The EMBO journal.
[28] A. Eastman,et al. Will targeting Chk1 have a role in the future of cancer therapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] T. Hunter,et al. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.
[30] P. O'Connor,et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.
[31] Xiao-yu Wu,et al. Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy , 2014, Journal of Experimental & Clinical Cancer Research.
[32] D. Haas-Kogan,et al. WEE1 Kinase As a Target for Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Grieco,et al. The end of mitosis from a phosphatase perspective , 2013, Cell cycle.
[34] G. Chan,et al. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2 , 2001, The Journal of cell biology.
[35] L. Karnitz,et al. Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo , 2007, Cell cycle.
[36] T. Buchholz,et al. MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells , 2011, Clinical Cancer Research.
[37] S. Robinson,et al. CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs , 2012, Clinical Cancer Research.
[38] J. Doroshow,et al. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[40] Y. Shiloh,et al. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. , 2013, Nature reviews. Molecular cell biology.
[41] N. Mailand,et al. Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.
[42] D. Grieco,et al. New insights on oxidative stress in cancer. , 2009, Current opinion in drug discovery & development.
[43] J. Doroshow,et al. The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial , 2005, Clinical Cancer Research.
[44] K. Cimprich. Probing ATR Activation with Model DNA Templates , 2007, Cell cycle.
[45] Yair Benita,et al. Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy , 2013, Molecular Cancer Therapeutics.
[46] Yasushi Okuno,et al. Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS , 2011, Journal of experimental & clinical cancer research : CR.
[47] A. Fattaey,et al. Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity* , 1997, The Journal of Biological Chemistry.
[48] M. Ernstoff,et al. Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) , 2006, Clinical Cancer Research.
[49] D. Grieco,et al. Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit , 2012, Nature Communications.
[50] J. Bartek,et al. DNA damage checkpoints: from initiation to recovery or adaptation. , 2007, Current opinion in cell biology.
[51] S. Elledge,et al. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.
[52] D. Grieco,et al. Fcp1 phosphatase controls Greatwall kinase to promote PP2A-B55 activation and mitotic progression , 2015, eLife.
[53] K. Cimprich,et al. ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.
[54] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[55] L. Galluzzi,et al. Mitotic catastrophe: a mechanism for avoiding genomic instability , 2011, Nature Reviews Molecular Cell Biology.
[56] H. B. El-Nassan,et al. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. , 2013, European journal of medicinal chemistry.
[57] Helder Maiato,et al. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. , 2004, Developmental cell.
[58] Stephen S. Taylor,et al. How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.
[59] M. Bui,et al. MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells , 2011, Molecular Cancer Therapeutics.
[60] A. Eastman,et al. Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites , 2011, Molecular Cancer Therapeutics.
[61] N. Xu,et al. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl‐2/Bax family proteins during treatment with microtubule interfering agents , 2014, Cell biology international.
[62] G. Peng,et al. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. , 2013, Cellular signalling.
[63] N. Turner,et al. Tumour selective targeting of cell cycle kinases for cancer treatment. , 2013, Current opinion in pharmacology.
[64] A. Ashworth,et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. , 2012, Cancer discovery.
[65] T. Chambers,et al. Identification of a mitotic death signature in cancer cell lines. , 2014, Cancer letters.
[66] N. Curtin,et al. Targeting the S and G2 checkpoint to treat cancer. , 2012, Drug discovery today.
[67] S. Patzke,et al. Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption , 2012, Molecular and Cellular Biology.
[68] N. Mailand,et al. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.
[69] S. Chandna,et al. Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide. , 2011, Current cancer drug targets.
[70] Conly L. Rieder,et al. Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.
[71] Paraskevi Giannakakou,et al. Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.
[72] J. Sarkaria,et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines , 2011, British Journal of Cancer.
[73] Y Taya,et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.
[74] J. Bartek,et al. Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation , 2004, Cancer Research.
[75] David A. Smith,et al. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer , 2016, Investigational New Drugs.
[76] Xiaoxiao Hu,et al. miRNA response to DNA damage. , 2011, Trends in biochemical sciences.
[77] W. Mellado,et al. Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.
[78] Mark T. W. Ebbert,et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer , 2012, Breast Cancer Research and Treatment.
[79] E. Sausville,et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[80] C. Sherr. Cancer Cell Cycles , 1996, Science.
[81] E. Salmon,et al. The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.
[82] Jonathan Maybaum,et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells , 2009, Molecular Cancer Therapeutics.
[83] Yuan Zhang,et al. The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity , 2009, Journal of experimental & clinical cancer research : CR.
[84] S. Elledge,et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.
[85] A. Eastman,et al. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[86] R. Medema,et al. Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.
[87] S. Haggarty,et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.
[88] A. Gunasekera,et al. Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents* , 2003, Journal of Biological Chemistry.
[89] Hua-mei Tang,et al. Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer , 2015, Journal of Experimental & Clinical Cancer Research.
[90] Stephen S. Taylor,et al. Mitosis and apoptosis: how is the balance set? , 2013, Current opinion in cell biology.
[91] Jiri Bartek,et al. Cell-cycle checkpoints and cancer , 2004, Nature.